Joint Request for Application in pancreatic and biliary tract cancer
BRUSSELS - The Anticancer Fund and the Rising Tide Foundation for Clinical Cancer Research have joined forces to support high impact clinical trials testing novel and unique strategies in the treatment of patients diagnosed with pancreatic ductal adenocarcinomas (PDAC) and/or biliary tract cancer (BTC).
The Anticancer Fund and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), a Swiss non-profit organisation, are looking for innovative approaches extrapolated from laboratory work in relevant cancer models or extrapolated from other cancer types but deemed applicable in PDAC and/or BTC (*). We are open to receive early to late-stage clinical trials (e.g., pilot study, Phase I, Phase II or Phase III). We welcome applications from all research groups with a track record in PDAC and/or BTC.
(*) Biliary tract cancers (BTC’s) constitute epithelial malignancies of the biliary tree and include the following: gallbladder cancer, ampulla of Vater cancer, cancer of the extra-hepatic and intra-hepatic bile ducts.
The amount available for this call for proposals is 3 million US dollars.
The amount allocated per grant will depend on the number of proposals selected for funding.
We kindly ask applicants to submit their Letter of Intent the latest on the 30th of June, 2021. We are planning to communicate the winning proposals in the fourth quarter of 2021.
More details about the scope of this Request for Application (RFA) and how to apply, can be found here.
The Anticancer Fund and the Rising Tide Foundation decided to join forces for this call as there is a need and urge to find new treatment options for patients with pancreatic cancer. Despite all recent innovation in cancer therapies, pancreatic cancer patients have very poor prognosis. The 5-year survival rate at an davanced stage is only 3%. Moreover, pancreatic cancer accounts for about 7% of all cancer deaths today. The ultimate goal of the Anticancer Fund and the Rising Tide Foundation is to make a difference and to help improve patient outcomes.
About the Rising Tide Foundation for Clinical Cancer Research
Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is a charitable, non-profit organization established in 2010 and located in Schaffhausen Switzerland. RTFCCR’s primary consideration in granting support is given to truly innovative, unique, patient-centered clinical research. The long-term ambition of the foundation is to optimize partnerships and attract the best in Phase I to Phase III clinical trials that aim to bring maximum patient benefit in the shortest time possible. With patients at the core of the mission, the foundation strives to support clinical trials resulting in the creation of less toxic therapeutic approaches, better disease burden management, earlier cancer detection, and innovative prevention strategies that will lead to increased quality of life and survival.
More information about how the Anticancer Fund supports clinical trials:
Find out more on our Apply for Funding page here.
Learn more about our involvement in clinical trials here.
Discover the trials we support here.